23andMe sees independent board directors quit en masse

23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink. Fading interest in DNA kits – 23andMe's main product – was one driver. So was news last year that hackers stole ancestry data on 6.9 million of its users. CEO and co-founder Anne Wojcicki now reportedly wants to take the 18-year-old company private. After her own proposal to buy it was rebuffed by its board in July, she was given time to w ...